Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
O95267

UPID:
GRP1_HUMAN

ALTERNATIVE NAMES:
Calcium and DAG-regulated guanine nucleotide exchange factor II; Ras guanyl-releasing protein

ALTERNATIVE UPACC:
O95267; Q56CZ0; Q58G75; Q59HB1; Q5I3A8; Q6GV31; Q6NX39; Q7LDG6; Q9UI94; Q9UNN9

BACKGROUND:
The RAS guanyl-releasing protein 1, identified by its involvement in calcium- and DAG-regulated nucleotide exchange, is a key regulator of the Ras signaling pathway. It facilitates the activation of Ras, influencing the Erk/MAP kinase cascade and playing a significant role in immune cell function, including T-cell/B-cell differentiation, NK cell activity, and mast cell responses. Its regulatory capacity extends to various cellular processes critical for immune system homeostasis.

THERAPEUTIC SIGNIFICANCE:
Linked to systemic lupus erythematosus and immunodeficiency 64, RAS guanyl-releasing protein 1's dysfunction highlights its potential as a therapeutic target. Abnormalities in this protein's expression or function can disrupt immune regulation, leading to disease. Exploring its mechanisms offers a promising avenue for developing treatments for these complex conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.